Literature DB >> 22237781

Cancer statistics, 2012.

Rebecca Siegel1, Deepa Naishadham, Ahmedin Jemal.   

Abstract

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. A total of 1,638,910 new cancer cases and 577,190 deaths from cancer are projected to occur in the United States in 2012. During the most recent 5 years for which there are data (2004-2008), overall cancer incidence rates declined slightly in men (by 0.6% per year) and were stable in women, while cancer death rates decreased by 1.8% per year in men and by 1.6% per year in women. Over the past 10 years of available data (1999-2008), cancer death rates have declined by more than 1% per year in men and women of every racial/ethnic group with the exception of American Indians/Alaska Natives, among whom rates have remained stable. The most rapid declines in death rates occurred among African American and Hispanic men (2.4% and 2.3% per year, respectively). Death rates continue to decline for all 4 major cancer sites (lung, colorectum, breast, and prostate), with lung cancer accounting for almost 40% of the total decline in men and breast cancer accounting for 34% of the total decline in women. The reduction in overall cancer death rates since 1990 in men and 1991 in women translates to the avoidance of about 1,024,400 deaths from cancer. Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population, with an emphasis on those groups in the lowest socioeconomic bracket.
Copyright © 2012 American Cancer Society, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22237781     DOI: 10.3322/caac.20138

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  2000 in total

1.  Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets.

Authors:  Keith T Flaherty
Journal:  Clin Exp Metastasis       Date:  2012-06-03       Impact factor: 5.150

2.  Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction.

Authors:  Xin Jin; Yunqian Pan; Liguo Wang; Tao Ma; Lizhi Zhang; Amy H Tang; Daniel D Billadeau; Heshui Wu; Haojie Huang
Journal:  Cancer Res       Date:  2017-07-18       Impact factor: 12.701

3.  68Ga-NOTA-RM26 PET/CT in the Evaluation of Breast Cancer: A Pilot Prospective Study.

Authors:  Jie Zang; Feng Mao; Hao Wang; Jingjing Zhang; Qingxing Liu; Li Peng; Fang Li; Lixin Lang; Xiaoyuan Chen; Zhaohui Zhu
Journal:  Clin Nucl Med       Date:  2018-09       Impact factor: 7.794

4.  Classification using ensemble learning under weighted misclassification loss.

Authors:  Yizhen Xu; Tao Liu; Michael J Daniels; Rami Kantor; Ann Mwangi; Joseph W Hogan
Journal:  Stat Med       Date:  2019-01-04       Impact factor: 2.373

5.  Estimation of exposure distribution adjusting for association between exposure level and detection limit.

Authors:  Yuchen Yang; Brent J Shelton; Thomas T Tucker; Li Li; Richard Kryscio; Li Chen
Journal:  Stat Med       Date:  2017-05-16       Impact factor: 2.373

6.  Liver recurrence in early endometrial cancer with focal myometrial invasion.

Authors:  Jung-Woo Park; Sung Ook Hwang; Suk-Jin Choi; Byoung Ick Lee; Jee Hyun Park; Eun Seop Song
Journal:  Obstet Gynecol Sci       Date:  2013-09-14

Review 7.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  HE4 combined with CA125: favorable screening tool for ovarian cancer.

Authors:  Nasrin Ghasemi; Samira Ghobadzadeh; Mahnaz Zahraei; Hemn Mohammadpour; Salahadin Bahrami; Mohammad Bakhshi Ganje; Shokoh Rajabi
Journal:  Med Oncol       Date:  2013-12-10       Impact factor: 3.064

9.  A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.

Authors:  Hailing Cheng; Pixu Liu; Fan Zhang; Erbo Xu; Lynn Symonds; Carolynn E Ohlson; Roderick T Bronson; Sauveur-Michel Maira; Emmanuelle Di Tomaso; Jane Li; Andrea P Myers; Lewis C Cantley; Gordon B Mills; Jean J Zhao
Journal:  Cancer Res       Date:  2013-12-09       Impact factor: 12.701

10.  Prognostic value of FDG uptake in primary inoperable non-small cell lung cancer.

Authors:  An-Na Tong; Shao-Rong Han; Peng Yan; Hai Gong; Hui Zhao; Hui Yao; Yan-Ming Wang
Journal:  Med Oncol       Date:  2013-12-11       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.